Langerhans Cell Histiocytosis (LCH)



Granulomatous Lesions comprising langerin-positive histiocytes and an inflammatory infiltrate can arise in virtually any organ system but have a particular affinity for bone, skin, lungs, and the pituitary.



WHAT?

• Definition: LCH is a rare disorder characterized by the proliferation of Langerhans cells, a type of dendritic cell involved in immune responses. These cells accumulate in various tissues, leading to damage and the formation of granulomas.

• Not purely inflammatory or autoimmune – now classified as a myeloid neoplasm

• Nature of Disease: LCH exhibits features of both inflammatory and neoplastic processes.

• Clonal proliferation of CD1a+, CD207+ (langerin+) dendritic cells.

• Part of the histiocytic neoplasms, often driven by MAPK pathway mutations (e.g., BRAF V600E)



WHEN?

• Incidence: 4–5 cases per million children/year.

• Affects both children and adults, male > female.

• Increased risk in some ethnicities (e.g., Hispanic populations)



CLINICAL SPECTRUM

Common areas include the bones, skin, lungs, and pituitary gland

• Bone Lesions: Painful lytic lesions, commonly in the skull, ribs, and long bones.

• Skin Involvement: Rashes, seborrheic dermatitis-like lesions.

• Endocrine Dysfunction: Diabetes insipidus due to pituitary involvement.

• Lymphadenopathy: Swollen lymph nodes.

• Pulmonary Symptoms: Cough, dyspnea, particularly in adult smokers.



A. Single-System (Low Risk)

Bone: Lytic lesions.

Skin: Papules, rashes.

Lungs: Cysts (esp. in smokers).



B. Multisystem (High Risk)

Liver, Spleen, Bone marrow: Organ dysfunction, cytopenias.

Pituitary involvement: Diabetes insipidus.

CNS involvement: Neurodegeneration, behavioral changes.



Histology & Immunophenotyping:

• Large pale histiocytes with reniform nuclei

• Birbeck granules (EM)

• Immunohistochemistry: CD1a+, CD207+ (langerin), S100+.



DIAGNOSIS

• Imaging: X-rays, CT, or MRI to identify lesions. PET-CT / MRI: Staging, detecting occult lesions.

• Biopsy: Confirmation through histological examination showing Langerhans cells positive for CD1a and Langerin (CD207).

• Laboratory Tests: Blood tests to assess organ function and rule out other conditions.



TREATMENT OPTIONS

Localized Disease:

• Surgical curettage or limited radiation therapy.

Multisystem Disease:

• Chemotherapy regimens, commonly vinblastine and prednisone.

• Targeted therapies for cases with BRAF V600E mutations.

• Supportive Care:

• Hormone replacement for endocrine dysfunctions.

• Smoking cessation is crucial in pulmonary LCH.



PROGNOSIS

• Single-System Disease: Generally favorable with appropriate treatment.

• Multisystem Disease: Prognosis varies; involvement of risk organs like the liver, spleen, or bone marrow indicates a more guarded prognosis.



#LCH #Langerhans #Cell #Histiocytosis #Diagnosis #Management